Tenaya Therapeutics, Inc. (TNYA) stock
TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.29−0.01 (-3.99%)
Close on Nov 20, 2026Market cap $64.26MP/E –Yield –
Tenaya Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Tenaya Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$52.59M. For fiscal 2025 it was -$68.88M. The highest annual figure on record is -$45.21M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.88M | – |
| FY2024 | Dec 31, 2024 | -$91.53M | – |
| FY2023 | Dec 31, 2023 | -$103.31M | – |
| FY2022 | Dec 31, 2022 | -$125.05M | – |
| FY2021 | Dec 31, 2021 | -$85.93M | – |
| FY2020 | Dec 31, 2020 | -$45.21M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.71M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.01M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.50M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.59M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.69M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.32M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.43M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.92M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.48M | – |
| Q3 FY2022 | Sep 30, 2022 | -$31.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$32.61M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.35M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.90M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.26M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.70M | – |
See a number that looks wrong?